Novo Nordisk

Bags Sword, Denmark Founded: 1923 • Age: 103 yrs Listed
Drugs for diabetes, obesity, hemophilia, and hormone therapy are manufactured.

About Novo Nordisk

Novo Nordisk is a publicly listed company based in Bags Sword (Denmark) founded in 1923. Drugs for diabetes, obesity, hemophilia, and hormone therapy are manufactured. It operates on a Direct-to-Consumer (D2C) and Professional Services model. Novo Nordisk has raised $145 thousand across 9 funding rounds from investors including European Union and IFU. The company has 61,878 employees. Novo Nordisk has completed 13 acquisitions, including Akero Therapeutics, Biocorp and Calibrium. Its chief executive, as recorded, is Lars Fruergaard Jorgensen. Its website novonordisk.com draws about 638 thousand monthly visits. Its Indian entity Novo Nordisk Service Centre (India) Private Limited reported revenue of ₹1,921 Cr. Novo Nordisk offers products and services including Ozempic, Wegovy, and Cagrilintide. Its focus areas include Pharmaceuticals and Biotechnology.

Company details

Novo Nordisk is focused on the development and distribution of pharmaceutical products targeting chronic conditions such as diabetes and obesity. Solutions are provided in various therapeutic areas with an emphasis on innovative treatments. The company operates within the healthcare sector, prioritizing science and technology to address unmet medical needs. Sustainable business practices are integrated into operations, alongside partnerships and a commitment to responsible sourcing. Global procurement strategies are employed to ensure quality and efficiency in supply chains.

  • Headquarters Bags Sword, Denmark
  • Employees 61,878
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website novonordisk.com
  • Social LinkedIn X Facebook Instagram YouTube
  • Legal Name Novo Nordisk A/S Class B
Key Metrics
  • Indian entity revenue
    ₹1,921 Cr

    FY 2025 · +38% YoY

  • Indian entity net profit
    ₹220 Cr

    FY 2025 · 11% margin

  • Indian entity EBITDA
    ₹386 Cr

    FY 2025 · 20% margin

  • Total Equity Funding
    $145K (USD)

    in 9 rounds

  • Latest Funding Round
    $173.74K (USD), Grant

    Mar 2022

  • Investors
  • Employee Count
    61,878
  • Investments & Acquisitions

Products & Services of Novo Nordisk

Novo Nordisk offers a comprehensive portfolio of products and services, including Ozempic, Wegovy, and Cagrilintide.

Ozempic
Pharmaceuticals

Ozempic is used for reducing cardiovascular risks effectively.

Wegovy
Pharmaceuticals

Wegovy is prescribed for weight loss management purposes.

Cagrilintide
Pharmaceuticals

Cagrilintide is developed for advanced obesity treatment solutions.

Apps and channels of Novo Nordisk

its YouTube channel Novo Nordisk has 3.52K subscribers and 30 videos.

Novo Nordisk
YouTube 3.52K subscribers 30 videos Howto & Style
Open channel

Videos from Novo Nordisk

The most watched videos on Novo Nordisk's YouTube channel, Novo Nordisk (3.52K subscribers). Click a video to play it here.

"Otro año que me ha pillado la primavera…” 🏵️ | #Cardiobascúlate (Novo Nordisk)
473.8K views
"Fútbol, pasión… ¿pero sin moverse? ⚽” | #Cardiobascúlate (Novo Nordisk)
267.2K views
"Fútbol, pasión… ¿pero sin moverse? ⚽” | #Cardiobascúlate (Novo Nordisk)
215.5K views
11 Seconds: Ina Montt
167.3K views

More on Novo Nordisk.

Funding Insights of Novo Nordisk

Novo Nordisk has successfully raised a total of $145K across 9 strategic funding rounds. The most recent funding activity was a Grant round of $173.74 thousand completed in March 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $145,000
  • Total Rounds 9
  • Last Round Grant — $173,745
  • First Round $145,000

    (Jun 1984)

  • Investors Count 2

All 9 funding rounds of Novo Nordisk with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Mar 2022$173,745Grant––
Jan 2021$364,871Grant––
Jan 2020Grant––
Jan 2018$348,415Grant––
Sep 2016$649,668Grant––
Jan 2015$350,669Grant––
Sep 2012$10,027Grant––
Jun 2011$1.74MPost-IPO––
Jun 1984$145,000Private Equity Round–IFU
–
Valuation history

2 investors in total: 2 institutional.

Investors in Novo Nordisk

Novo Nordisk has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include European Union and IFU.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Private equity investment firm
1967ifu.dkCopenhagen, Denmark
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
1958europa.euBrussels, Belgium
Premium access

Investor details for Novo Nordisk

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Novo Nordisk Service Centre (India) Private Limited (Novo Nordisk)

Novo Nordisk Service Centre (India) Private Limited is the primary company behind Novo Nordisk. The board of Novo Nordisk Service Centre (India) Private Limited currently have 4 directors; the longest-serving is Soren Thor Jensen, appointed in 2012. 13 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Soren Thor Jensen
DIN 05173608
Director09 Mar 201214 yrs 8 moNovo Nordisk Service Centre (India) Private Limited
Lene Hylling Axelsson
DIN 08470408
Director16 Oct 20197 yrs 1 moNovo Nordisk Service Centre (India) Private Limited
Vikrant Shrotriya
DIN 08635146
Director11 Nov 20215 yrsNovo Nordisk Service Centre (India) Private Limited
John Christopher Dawber
DIN 09812822
Managing Director29 Sep 20233 yrs 1 moNovo Nordisk Service Centre (India) Private Limited

People of Novo Nordisk

1137 people are tracked at Novo Nordisk (546 in leadership, 9 in board & advisors, 582 in team); the tracked headcount is 61,878.

NameRoleGroup
Lars Fruergaard Jorgensen
CEO & PresidentLeadership
Anne-Kristine Prag Steinitz
Corporate Vice President Strategic Scientific Communication, Global Medical AffairsLeadership
Cecilie Heerdegen Jepsen
Head Of Translational MedicineLeadership
Malgorzata Wnuk
Strategic Finance & Project DirectorLeadership
Allegra Kaufman
Executive Director, Clinical Development StrategyLeadership
Greg Horikoshi
Associate Director Commercial ExecutionLeadership
Claudia Laven
Vice President | Obesity CareLeadership
David Scott
Director, Legal, Ethics, Compliance And QualityLeadership
Sofie Inari Castella
Global Director, Scientific PublicationsLeadership
Rasmus Sonne Henniker Heaton
Sr. Business & Project PartnerLeadership
Ghita Bahbouhi
Supply Chain Analytics PartnerLeadership
Teresa Sophie K.
Director, IME & Medical Association PartnershipsLeadership
Ulrik Ullum
Senior DirectorLeadership
Katy Long
Snr Dir, HR Business Partner, International OperationsLeadership
Victor Vazquez
Talent Acquisition Partner Americas (latam, USA & Canada)Leadership
Al Willis
Senior Director - Deployment Strategy & Sales InnovationLeadership
Morten Engelund
Corporate Vice President, Total Rewards And MobilityLeadership
Briana Dunn
Associate Director Search And EvaluationLeadership
Jacob Sten Petersen
Corporate Vice President, Stem Cell R&DLeadership
Konstantinos Ratsikas
Senior Supply Chain PartnerLeadership

1117 more people are available in the full profile.

Premium access

Complete people profiles for Novo Nordisk

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Novo Nordisk

Novo Nordisk is a publicly listed company on the OMXCOP with ticker symbol NOVO_B in Denmark, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date07 Jan 2000
  • Listed onNASDAQ: NOVO B
  • Listed entityNovo Nordisk A/S Class B
  • Exchange sectorHealth technology
  • ISINDK0062498333
  • Share price253.60 DKK (-1.19% on the day) · 2026-10-14
  • Market capitalisation1,137,691,183,097.00 DKK
  • Price to earnings9.7
  • EPS (diluted, trailing year)26.19 DKK
  • Dividend yield4.56%
  • Volume (last session)278,302

Financials of Novo Nordisk

Figures of Novo Nordisk Service Centre (India) Private Limited, the primary company behind Novo Nordisk, for FY 2025. Revenue was ₹1,921 Cr (+38% year on year). Net profit was ₹220 Cr (11% margin). EBITDA was ₹386 Cr (20% margin). Revenue has grown at a compounded annual rate of +39% over three years and +28% over five years.

  • ₹1,921 CrRevenue · FY 2025 · +38% YoY
  • ₹220 CrNet profit · 11% margin
  • ₹386 CrEBITDA · 20% margin
  • ₹4.01 CrPaid-up capital
  • 3,480Employees (provident fund records)
  • +39%Revenue CAGR, 3 years
  • +28%Revenue CAGR, 5 years
Exchange-reported annual figures
YearRevenueNet incomeEBITDA
2025309.06B DKK102.43B DKK149.69B DKK
2024290.40B DKK100.99B DKK147.95B DKK
2023232.26B DKK83.68B DKK111.38B DKK
2022176.95B DKK55.52B DKK81.02B DKK
2021140.80B DKK47.76B DKK64.32B DKK

Balance sheet, profit and loss, cash flow and ratios of Novo Nordisk Service Centre (India) Private Limited are on its company page.

Premium access

Detailed financial statements for Novo Nordisk

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Novo Nordisk

Novo Nordisk has strategically engaged in corporate development activities, having acquired 13 companies. Notable acquisitions include Akero Therapeutics, Biocorp and Calibrium.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Small molecule therapeutics for metabolic disorders are developed.
akerotx.comSan Francisco, United States2017Oct 2025$4.7B
Non-coding RNA therapeutics are developed for cardiovascular disease treatment.
cardior.deHannover, Germany2016Mar 2024••••
Multiple courses and degrees are offered across diversified academic streams.
ku.dkCopenhagen, Denmark1479Sep 2023••••
Novel therapeutics for metabolic diseases and obesity are developed.
embarkbiotech.comCopenhagen, Denmark2017Aug 2023••••
Drug delivery systems and medical devices are developed and manufactured.
biocorpsys.comIssoire, France2004Jun 2023$164.87M
Developer of therapeutic solutions for multiple health purposes
formatherapeutics.comWatertown, United States2007Sep 2022$1.1B
Drugs are developed using RNA interference technology platform.
dicerna.comLexington, United States2007Nov 2021$3.3B
Technology for delivery of therapeutic molecules
emisphere.comRoseland, United States1986Nov 2020$1.8B
Cardiovascular therapies are developed using functional genomics approaches.
corvidiatx.comWaltham, United States2015Jun 2020$725M
Biosensor platforms for carbohydrates are developed using photonics and optoelectronics.
ziylo.comBristol, United Kingdom2014Aug 2018$800M
Premium access

Complete acquisition details for Novo Nordisk

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Novo Nordisk

14 dated milestones of Novo Nordisk across 102 years, from founding to its latest funding, stage changes and deals.

  1. Founded Novo Nordisk is founded.
  2. Funding First funding round of $145K.
  3. IPO Lists on the stock exchange (IPO).
  4. Acquisition Acquires Ziylo.
  5. Acquisition Acquires Corvidia Therapeutics.
  6. Acquisition Acquires Emisphere.
  7. Acquisition Acquires Dicerna Pharmaceuticals.
  8. Funding Latest funding round, Grant, of $174K.
  9. Acquisition Acquires Forma Therapeutics.
  10. Acquisition Acquires Biocorp.
  11. Acquisition Acquires Embark Biotech.
  12. Acquisition Acquires University of Copenhagen.
  13. Acquisition Acquires Cardior Pharmaceuticals.
  14. Acquisition Acquires Akero Therapeutics.

Web traffic of Novo Nordisk

The website of Novo Nordisk (novonordisk.com) receives about 637.8K visits a month and ranks #83,485 among all websites worldwide, #2,383 in Health.

  • Monthly visits
    637.8K

    ▼ 0.5% vs previous month

  • Unique visitors
    299.1K

    per month

  • Global rank
    #83,485

    among all websites

  • Category rank
    #2,383

    Health · Health

Similar websites

Websites whose visitors overlap most with Novo Nordisk. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
lilly.com
100%
4.9M#13,252View details
novonordisk-us.com
96%
89K#469,241View details
gsk.com
84%
1.3M#56,834View details
novartis.com
77%
948.8K#58,822View details
abbott.com
77%
917.2K#65,577View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 40 similar websites and full traffic analytics for Novo Nordisk

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 40 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Novo Nordisk

Premium access

Complete news archive for Novo Nordisk

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Novo Nordisk

Novo Nordisk was founded in 1923 and raised its 1st funding round 61 years after it was founded.

Novo Nordisk is headquartered in Bags Sword, Denmark.

Lars Fruergaard Jorgensen is the CEO of Novo Nordisk, as recorded in our data.

Novo Nordisk is a funded company, having raised a total of $145K across 9 funding rounds to date. The company's 1st funding round was a Private Equity Round of $145K, raised on Jun 1984.

Novo Nordisk has 61,878 employees.

The primary company behind Novo Nordisk, Novo Nordisk Service Centre (India) Private Limited, reported revenue of ₹1,921 Cr for FY 2025, up 38% year on year.

Novo Nordisk is focused on the development and distribution of pharmaceutical products targeting chronic conditions such as diabetes and obesity. Solutions are provided in various therapeutic areas with an emphasis on innovative treatments. The company operates within the healthcare sector, prioritizing science and technology to address unmet medical needs. Sustainable business practices are integrated into operations, alongside partnerships and a commitment to responsible sourcing. Global procurement strategies are employed to ensure quality and efficiency in supply chains.

Novo Nordisk offers Ozempic, Wegovy, and Cagrilintide.

Yes, Novo Nordisk is publicly traded on OMXCOP under the ticker symbol NOVO_B.

Novo Nordisk has made 13 acquisitions, including Akero Therapeutics, Biocorp, and Calibrium.

Novo Nordisk has 2 investors. Key investors include European Union, and IFU.

Novo Nordisk operates through Novo Nordisk Service Centre (India) Private Limited.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available